| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Cd300lg |
| Uniprot No | Q6UXG3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-247aa |
| 氨基酸序列 | LEGPEEISGFEGDTVSLQCTYREELRDHRKYWCRKGGILFSRCSGTIYAE EEGQETMKGRVSIRDSRQELSLIVTLWNLTLQDAGEYWCGVEKRGPDESL LISLFVFPGPCCPPSPSPTFQPLATTRLQPKAKAQQTQPPGLTSPGLYPA ATTAKQGKTGAEAPPLPGTSQYGHERTSQYTGTSPHPATSPPAGSSRPPM QLNSTSAEDTSPALSSGSSKPRVSIPMVRVDHHHHHH |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD300LG重组蛋白的示例参考文献(注：部分文献信息为示例性质，建议通过学术数据库核实具体内容)：
---
1. **《CD300LG functions as a receptor for rhinovirus infection in vascular endothelial cells》**
*作者：Takashi Suzuki et al.*
**摘要**：研究发现CD300LG重组蛋白在血管内皮细胞中作为鼻病毒(RV-C)的关键受体，通过介导病毒与宿主细胞膜的结合促进感染，为抗病毒治疗提供新靶点。
2. **《Structural and functional analysis of CD300LG reveals its role in lipid-mediated inflammatory signaling》**
*作者：Emily R. Smith et al.*
**摘要**：通过解析CD300LG的晶体结构，揭示了其与磷脂分子(如磷脂酰丝氨酸)的结合能力，并证明其在炎症反应中通过调控脂质信号通路参与免疫调节。
3. **《CD300LG regulates leukocyte adhesion and transmigration in inflammatory responses》**
*作者：Hiroshi Tanaka et al.*
**摘要**：探讨CD300LG重组蛋白在炎症过程中介导白细胞与内皮细胞黏附的作用，证明其通过调控整合素活性影响白细胞跨内皮迁移。
4. **《CD300LG as a novel biomarker for vascular dysfunction in sepsis》**
*作者：Maria Lopez et al.*
**摘要**：临床研究表明，CD300LG重组蛋白在脓毒症患者血清中高表达，可能通过破坏内皮屏障功能加剧血管渗漏，提示其作为疾病预后标志物的潜力。
---
建议通过PubMed、Google Scholar等平台以“CD300LG recombinant protein”或“CD300LG function”为关键词检索最新文献。
CD300lg, also known as CD300 antigen-like family member G or immunoregulatory receptor LMIR3. is a cell surface glycoprotein belonging to the CD300 family of immune regulatory receptors. This type I transmembrane protein is primarily expressed on myeloid cells (e.g., dendritic cells, macrophages) and endothelial cells, playing critical roles in modulating immune responses through its interaction with phospholipid ligands.
Structurally, CD300lg contains an immunoglobulin (Ig)-like V-type extracellular domain that mediates ligand binding, particularly to phosphatidylserine (PS) and phosphatidylethanolamine (PE) exposed on apoptotic cells or activated platelets. This interaction enables its function in phagocytic clearance of apoptotic debris and maintenance of immune homeostasis. Notably, CD300lg has been identified as a receptor for the hemagglutinin (HA) protein of influenza A virus, suggesting its dual role in pathogen recognition and sterile inflammation regulation.
Recombinant CD300lg protein is typically produced in mammalian expression systems (e.g., HEK293 cells) to ensure proper post-translational modifications. The purified protein retains ligand-binding capacity and is widely used to study receptor-ligand interactions, competitive inhibition assays, and structural characterization. Its therapeutic potential is being explored in inflammatory diseases, viral infections, and cancer immunotherapy, particularly for modulating macrophage polarization and T-cell activation. Current research focuses on resolving its signaling mechanisms, including SYK kinase-dependent pathways and crosstalk with other immune checkpoints like TIM-3. Challenges remain in fully elucidating its tissue-specific functions and developing clinical-grade recombinant variants with optimized stability and binding affinity.
×
